Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 05, 2015 6:46 AM ET

Biotechnology

Company Overview of Acceleron Pharma, Inc.

Company Overview

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of protein therapeutics for cancer and rare diseases. The company is developing luspatercept and sotatercept therapeutic candidates, which are in Phase 3 clinical trials used to treat anemia and associated complications in patients with ß-thalassemia and myelodysplastic syndromes. The sotatercept therapeutic candidate is also used to increase bone mineral density; and to treat the final stage of chronic kidney disease and end-stage renal disease. It is also developing dalantercept therapeutic candidate to treat renal cell carcinoma and hepatocellular carcinoma; and ...

128 Sidney Street

Cambridge, MA 02139

United States

Founded in 2003

83 Employees

Phone:

617-649-9200

Fax:

617-649-9988

Key Executives for Acceleron Pharma, Inc.

Founder, Chief Executive Officer, President and Director
Age: 63
Total Annual Compensation: $460.0K
Chief Financial Officer, Senior Vice President and Treasurer
Age: 59
Total Annual Compensation: $325.0K
Chief Operating Officer and Executive Vice President
Age: 46
Total Annual Compensation: $335.0K
Chief Medical Officer and Executive Vice President
Age: 59
Total Annual Compensation: $392.0K
Senior Vice President, General Counsel and Secretary
Age: 44
Total Annual Compensation: $335.0K
Compensation as of Fiscal Year 2014.

Acceleron Pharma, Inc. Key Developments

Acceleron Pharma, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Acceleron Pharma, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company's collaboration revenue was $5,717,000 compared with $4,078,000 a year ago. Loss from operations was $13,094,000 compared with $17,311,000 a year ago. Net loss applicable to common stockholders was $10,383,000 or $0.32 per share compared with $16,550,000 or $0.52 per share a year ago. For the six months, the company's collaboration revenue was $10,139,000 compared with $7,385,000 a year ago. Loss from operations was $28,151,000 compared with $29,519,000 a year ago. Net loss applicable to common stockholders was $24,955,000 or $0.76 per share compared with $25,670,000 or $0.83 per share a year ago.

Acceleron Pharma, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Acceleron Pharma, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Acceleron Pharma Inc. Announces Publication in Cancer Research Demonstrating Dalantercept Prevents Metastases in Preclinical Studies of Breast Cancer

Acceleron Pharma Inc. announced that new study findings involving the use of dalantercept to block the activin receptor-like kinase 1 (ALK1) pathway for the treatment of metastatic breast cancer were published in the June 15th issue (volume 75, #12) of Cancer Research, a journal of the American Association for Cancer Research. These pre-clinical findings suggest that dalantercept, in addition to treating the primary tumor, may also have an effect on metastasis, the principal clinical issue in advanced disease. The role of ALK1 expression by endothelial cells in primary breast tumor vasculature is a prognostic biomarker for metastatic dissemination. The company used dalantercept to inhibit ALK1 in multiple mouse models of breast cancer, and in doing so, the company were able to prevent metastatic dissemination and specifically the spread of the primary breast tumor to the lungs.

Similar Private Companies By Industry

Company Name Region
Genset Corporation United States
Plough Boy Organics, LLC United States
Arrogene, Inc. United States
Prospex Medical, Inc. United States
Applied NeuroSolutions Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Acceleron Pharma, Inc., please visit www.acceleronpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.